Please check your internet connection and try again.
# Clobazam (Oral Formulation)
## Overview
Clobazam is a benzodiazepine derivative with anticonvulsant properties. It is primarily used as adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS) in pediatric and adult patients.
## Primary Indications
Adjunctive treatment of seizures in patients with Lennox-Gastaut syndrome (LGS).
## Adult Dosing
* **Initial Dose:** 5 mg orally twice daily.
* **Titration:** Increase dose by 5 mg to 10 mg every week based on clinical response and tolerability, up to a maximum of 20 mg twice daily.
* **Maintenance Dose:** Typically 10 mg to 20 mg orally twice daily.
## Pediatric Dosing
* **Age 2 years and older:**
* **Initial Dose:** 5 mg orally twice daily.
* **Titration:** Increase dose by 5 mg to 10 mg every week based on clinical response and tolerability.
* **Maximum Dose:** 10 mg twice daily for patients weighing less than 30 kg, and 20 mg twice daily for patients weighing 30 kg or more.
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. No specific dose adjustment guidelines are established, but a lower starting dose and slower titration may be warranted.
* **Renal Impairment:** Use with caution. No specific dose adjustment guidelines are established.
* **Concomitant Medications:** Consider dose reduction of clobazam or the interacting agent, especially with strong CYP3A4 inhibitors or inducers.
## Contraindications
* Hypersensitivity to clobazam or other benzodiazepines.
* Severe hepatic impairment.
## Adverse Effects
* **Common:** Somnolence, decreased appetite, constipation, aggression, irritability, fatigue, vomiting, drooling, ataxia, difficulty with speech.
* **Serious:** Suicidal behavior or ideation, severe drowsiness, respiratory depression, dependence and withdrawal symptoms, Stevens-Johnson syndrome/toxic epidermal necrolysis.
## Key Drug Interactions
* **CYP3A4 Substrates:** Clobazam is a moderate inhibitor of CYP2C19 and a substrate of CYP3A4. Concomitant use with other CNS depressants (e.g., alcohol, opioids, other benzodiazepines) may increase the risk of sedation and respiratory depression.
* **CYP2C19 Inhibitors/Inducers:** Clobazam can affect the metabolism of drugs that are substrates of CYP2C19 (e.g., proton pump inhibitors like omeprazole, clopidogrel).
* **Strong CYP3A4 Inhibitors (e.g., ketoconazole, ritonavir):** May increase clobazam plasma concentrations.
* **Strong CYP3A4 Inducers (e.g., rifampin, carbamazepine):** May decrease clobazam plasma concentrations.
## Monitoring
* Monitor for signs of sedation, respiratory depression, and cognitive impairment.
* Assess for behavioral changes, including suicidal ideation or behavior.
* Monitor for withdrawal symptoms upon discontinuation.
* Consider drug level monitoring if interactions are suspected or efficacy/toxicity is unclear.
## Clinical Pearls
* Clobazam should be tapered slowly upon discontinuation to avoid withdrawal symptoms.
* Due to the risk of serious skin reactions, patients should be advised to discontinue clobazam and seek immediate medical attention if they experience a rash, blistering, or peeling of the skin.
* Clobazam may cause dose-dependent increases in N-desmethylclobazam (norclobazam), its active metabolite, which contributes to its long duration of action and potential for accumulation.
***
**Disclaimer:** This information is intended for clinical use and does not replace professional judgment. Always refer to the most current prescribing information for complete details and to confirm dosages and safety information.
